ストックスクリーナーアプリを入手
0.341
8.12%
0.0256
アフターアワーズ：
.34
-0.001
-0.29%
前日終値:
$0.3154
開ける：
$0.302
24時間の取引高:
825.35K
Relative Volume:
1.36
時価総額：
$16.49M
収益：
$1.38M
当期純損益:
$-179.05M
株価収益率:
-0.048
EPS:
-7.11
ネットキャッシュフロー:
$-155.03M
1週間 パフォーマンス:
-17.25%
1か月 パフォーマンス:
-42.01%
6か月 パフォーマンス:
-70.09%
1年 パフォーマンス:
-88.52%
1日の値動き範囲:
$0.3001
$0.3441
1週間の範囲:
$0.3001
$0.52
52週間の値動き範囲:
$0.3001
$4.17
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
名前
Bioxcel Therapeutics Inc
セクター
電話
203-643-8060
住所
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
0.341 | 16.49M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-21 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-15 | ダウングレード | Mizuho | Buy → Neutral |
| 2023-07-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-03-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-12-01 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-04-06 | 繰り返されました | BofA Securities | Buy |
| 2021-11-15 | ダウングレード | Goldman | Neutral → Sell |
| 2021-04-09 | 開始されました | Berenberg | Buy |
| 2021-02-01 | 開始されました | UBS | Buy |
| 2020-10-30 | 開始されました | Goldman | Buy |
| 2020-09-02 | 開始されました | Jefferies | Buy |
| 2020-08-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-04 | 開始されました | Guggenheim | Buy |
| 2020-04-01 | 開始されました | BofA/Merrill | Buy |
| 2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
すべてを表示
Bioxcel Therapeutics Inc (BTAI) 最新ニュース
Bioxcel therapeutics CEO sells shares worth $1,131 By Investing.com - Investing.com Australia
Bioxcel therapeutics' chief scientific officer sells $151 worth of stock By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO Richard Steinhart sells $206 in stock - Investing.com India
Bioxcel therapeutics executive sells $153 in stock - Investing.com
Bioxcel therapeutics CEO sells shares worth $1,131 - Investing.com
Bioxcel therapeutics exec sells $58 in stock By Investing.com - Investing.com UK
BioXcel Therapeutics stock hits 52-week low at $0.35 - Investing.com India
BioXcel Therapeutics (STU:BX2) 5-Day RSI : 7.74 (As of Dec. 05, 2024) - GuruFocus.com
BioXcel Therapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada
BioXcel Therapeutics stock hits 52-week low at $0.4 - Investing.com India
BioXcel Therapeutics announces pricing of $7M public offering - MSN
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
BioXcel Therapeutics Prices of $7 Million Public Offering - citybiz
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
BioXcel Therapeutics announces $7M public offering - Hartford Business Journal
BioXcel Prices New Offering - Baystreet.ca
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewswire
BioXcel Therapeutics Announces $7M Public Offering at $0.48 Per Share with Warrants | BTAI Stock News - StockTitan
BioXcel Therapeutics amends credit agreement, issues new warrants - Investing.com
BioXcel Therapeutics amends credit agreement, issues new warrants By Investing.com - Investing.com Canada
BioXcel Therapeutics Announces Proposed Public Offering - GlobeNewswire
BioXcel Therapeutics Announces Proposed Public Offering - Benzinga
BioXcel Therapeutics Launches Public Offering to Fund Critical Clinical Trials | BTAI Stock News - StockTitan
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - MSN
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance
BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartzy
BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks
500: Something went wrong - Investing.com India
Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com
Earnings call: BioXcel Therapeutics reports Q3 2024 financials By Investing.com - Investing.com UK
BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada
BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
BioXcel Q3 Revenue Drops 37%, but Net Loss Narrows Significantly to $13.7M | BTAI Stock News - StockTitan
Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World
What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com
BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World
BioXcel advances trials for acute agitation treatments - Investing.com India
BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire
BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan
Bioxcel Therapeutics Inc (BTAI) 財務データ
収益
当期純利益
現金流量
EPS
Bioxcel Therapeutics Inc (BTAI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mehta Vimal | CEO and President |
Dec 16 '24 |
Sale |
0.36 |
3,117 |
1,131 |
59,605 |
| Steinhart Richard I | Chief Financial Officer |
Dec 16 '24 |
Sale |
0.36 |
577 |
207 |
20,932 |
| Rodriguez Javier | See Remarks |
Dec 16 '24 |
Sale |
0.36 |
430 |
153 |
24,423 |
| Yocca Frank | Chief Scientific Officer |
Dec 16 '24 |
Sale |
0.35 |
430 |
152 |
28,931 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):